Cystic Fibrosis Therapeutics Market Size, Share & Growth Report 2032

Cystic Fibrosis Therapeutics Market: Industry Perspective

The global cystic fibrosis therapeutics market size was worth around USD 6.02 billion in 2023 and is predicted to grow to around USD 20.70 billion by 2032 with a compound annual growth rate (CAGR) of roughly 14.82% between 2024 and 2032.

The report offers a valuation and analysis of the cystic fibrosis therapeutics market on a global and regional level. The study comprehensively assesses the industry competition, limitations, sales estimates, avenues, current & emerging trends, and industry-validated market data. The report offers historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on value (USD Billion).

Request Free Sample

Cystic Fibrosis Therapeutics Market: Introduction

Cystic fibrosis is a progressive genetic disorder & chronic condition that is caused due to mutations occurring in the cystic fibrosis transmembrane conductance regulator gene and obstructs the normal epithelia functioning in which it is present. Additionally, varied mutations in the gene have different impacts on the cystic fibrosis transmembrane conductance (CFTR) regulator resulting in various phenotypes of the disorder. Moreover, the most common gene mutation is phenylalanine occurring in codon 508 and it is found in nearly 70% of the persons suffering from cystic fibrosis. The disorder is mainly found in respiratory & gastrointestinal tracts.  According to NCBI, cystic fibrosis affects nearly 75,000 persons globally and is considered to be lethal with the large number of mutations in genes limiting lung functions. The detection of the cystic fibrosis gene in 1989 and a new understanding of cystic fibrosis transmembrane conductance regulator protein have resulted in the creation of novel cystic fibrosis therapies aimed at influencing protein function.  

Request Free Sample

The new kind of medical treatment termed cystic fibrosis transmembrane conductance regulator (CFTR) modulators are effectively targeting myriad kinds of mutations occurring in the cystic fibrosis transmembrane conductance regulator gene that is responsible for causing cystic fibrosis. These new therapies have demonstrated positive effects on patients suffering from cystic fibrosis and have encouraged the development of new therapies that can cure the disease. Moreover, the introduction of new treatments focusing on effectively managing chronic lung infection & airway clearance has shown positive results in the patients.

Cystic Fibrosis Therapeutics Market: Growth Dynamics

The breakthroughs in stem cell research and gene therapy have paved the way for the growth of the cystic fibrosis therapeutics market in recent years. Furthermore, the use of gene editing treatment will also contribute notably to the global cystic fibrosis therapeutics market size. Prominently, the new drug class referred to as CFTR (cystic fibrosis transmembrane conductance regulator) modulators can modify the defect in the CFTR protein and this will boost the market trends. For the record, CFTR modulators including Ivacaftor, Lumacaftor, and Orkambi are used for correcting defects in the CTFR gene to prevent cystic fibrosis.

Moreover, the introduction of anti-inflammatory therapy and mucus-alteration & airway surface liquid modulation therapy are anticipated to propel the market growth over 2024-2032. In addition to this, Pulmozyme treatment aids breathing in patients through the clearance of pulmonary obstructions caused due to cystic fibrosis. Another treatment for cystic fibrosis referred to as PERT that makes use of porcine-derived pancrelipase enzymes is used along with liprotamaase for treating cystic fibrosis and has exhibited favorable outcomes during clinical trials. Antimicrobial drugs are also being used for treating the disease and this will culminate in the surge in the market proceeds over the forthcoming years.

Cystic Fibrosis Therapeutics Market: Report Scope

Cystic Fibrosis Therapeutics Market: Regional Analysis

• North American Market To Retain Dominant Position Over 2024-2032

The growth of the market in the sub-continent over the forecast timespan is attributed to large-scale funding of research activities carried out by reputed pharma firms in the region for launching new drugs to cure the autosomal recessive disorder. Furthermore, breakthroughs witnessed in the biotechnology domain will further contribute to the regional market growth over the ensuing years.

Cystic Fibrosis Therapeutics Market: Competitive Analysis

The global cystic fibrosis therapeutics market is dominated by players like:

• Novartis AG
• Mylan N.V.
• Genentech, Inc.
• AbbVie Inc.
• Vertex Pharmaceuticals Incorporated
• Johnson & Johnson
• Gilead Sciences, Inc.
• GlaxoSmithKline Plc.
• Allergan plc
• Pharmaxis Ltd.

The global cystic fibrosis therapeutics market is segmented as follows:

By Drug Class

• Pancreatic Enzyme Supplements
• Mucolytic
• Bronchodilators
• CFTR modulators

By Route of Administration

• Oral
• Inhaled

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa